A recent review highlights inflammation’s dual role in cancer progression and how emerging tools like AI and imaging biomarkers are enhancing personalized immunotherapy.
Key Details
- 1Chronic inflammation promotes tumorigenesis, survival, and therapy resistance, but can also suppress cancer depending on context.
- 2Key pathways: NF-κB, STAT3, IL-6, COX-2, and specific immune cells modulate the tumor microenvironment.
- 3Immunotherapies show varying efficacy (20–40% response rates); biomarkers like CRP, IL-6, and imaging data are key for patient stratification.
- 4Combination strategies (immunotherapy plus anti-inflammatories or microbiome modulators) are under clinical investigation.
- 5AI models incorporating imaging and multi-omic data are enabling real-time treatment personalization; Stanford’s 2024 model integrates imaging/text.
- 6Emerging tools include liquid biopsies, single-cell omics, gene editing, and nanotechnology for more precise disease monitoring.
Why It Matters
Understanding how inflammation drives cancer and therapy resistance is crucial for radiology, especially as integration of imaging, AI, and novel biomarkers underpins the move toward precision oncology. These advances offer new avenues for diagnosis, patient stratification, and monitoring treatment response using imaging and AI-driven tools.
Source
EurekAlert
Related News
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
Deep Learning Pathomics Platform Improves Immunotherapy Prediction in Lung Cancer
A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.
•EurekAlert
AI Pathology Model Outperforms PD-L1 in Predicting NSCLC Immunotherapy Response
MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.